<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000822'>Hypertension</z:hpo> represents a major public and global health problem, most of which likely can be improved by lifestyle changes including changing dietary habits with less consumption of processed and preserved foods, which generally contain higher amounts of salt than freshly prepared food items </plain></SENT>
<SENT sid="1" pm="."><plain>Among causes for <z:chebi fb="32" ids="24621">endocrine</z:chebi> <z:hpo ids='HP_0000822'>hypertension</z:hpo> are syndromes of <z:hpo ids='HP_0000859'>mineralocorticoid excess</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>This group of mostly monogenic and acquired disorders typically causes <z:hpo ids='HP_0000822'>hypertension</z:hpo> through activation of the <z:chebi fb="0" ids="25354">mineralocorticoid</z:chebi> receptor either directly or indirectly via hormonal mediators and from overactive <z:chebi fb="0" ids="2639">amiloride</z:chebi>-sensitive epithelial <z:chebi fb="199" ids="26708">sodium</z:chebi> channels located in the distal tubule and collecting ducts of the kidneys </plain></SENT>
<SENT sid="3" pm="."><plain>Apart from <z:e sem="disease" ids="C1719312,C1384514" disease_type="Disease or Syndrome" abbrv="">primary aldosteronism</z:e>, <z:hpo ids='HP_0000859'>mineralocorticoid excess</z:hpo> can be caused by <z:hpo ids='HP_0008258'>congenital adrenal hyperplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CAH</z:e>) due to mutations of the 11beta-hydroxylase and 17alpha-hydroxylase genes, by inactivating mutations of the <z:chebi fb="1" ids="24261">glucocorticoid</z:chebi> receptor gene (Chrousos syndrome), endogenous <z:hpo ids='HP_0001578'>hypercortisolism</z:hpo> (<z:e sem="disease" ids="C0010481" disease_type="Disease or Syndrome" abbrv="">Cushing's syndrome</z:e>), by mutations of the <z:chebi fb="0" ids="35346">11beta-hydroxysteroid</z:chebi> dehydrogenase type 2 gene (apparent <z:hpo ids='HP_0000859'>mineralocorticoid excess</z:hpo>/AME) or licorice/carbenoxolone intake, mutations of the epithelial <z:chebi fb="199" ids="26708">sodium</z:chebi> channel genes (Liddle syndrome), mutations of the <z:chebi fb="0" ids="25354">mineralocorticoid</z:chebi> receptor gene (Geller syndrome), and by mutations in the WNK1, WNK4, KLHL3, CUL3 genes (<z:hpo ids='HP_0008242'>pseudohypoaldosteronism</z:hpo> type 2 or Gordon syndrome) </plain></SENT>
<SENT sid="4" pm="."><plain>Most of these conditions are treated by restricting dietary salt intake </plain></SENT>
<SENT sid="5" pm="."><plain>However, some require special therapies including <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>/<z:chebi fb="2" ids="17650">hydrocortisone</z:chebi> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CAH</z:e>), <z:chebi fb="0" ids="9241">spironolactone</z:chebi>/<z:chebi fb="0" ids="31547">eplerenone</z:chebi> (AME), epithelial <z:chebi fb="199" ids="26708">sodium</z:chebi> channel inhibitors <z:chebi fb="0" ids="2639">amiloride</z:chebi>/triamterene (Liddle and Gordon syndrome), while in others <z:chebi fb="0" ids="9241">spironolactone</z:chebi> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> <z:chebi fb="68" ids="48706">antagonists</z:chebi> may be contraindicated due to an abnormally structured <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> (Geller syndrome) </plain></SENT>
<SENT sid="6" pm="."><plain>We here review the pathophysiology, diagnosis, and therapy of these rare conditions including the presentation of a patient with <z:e sem="disease" ids="C0268292" disease_type="Disease or Syndrome" abbrv="">11beta-hydroxylase deficiency</z:e> </plain></SENT>
</text></document>